Phico Therapeutics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $9.7M

  • Investors
  • 20

Phico Therapeutics General Information

Description

Developer of an intravenous-engineered bacteriophage drug designed to treat ventilator-associated pneumonia. The company's drug uses engineered bacterial viruses combined with antibacterial small acid-soluble spore proteins to prevent the release of toxins, enabling physicians to target the pneumonia bacteria and inactivate its deoxyribonucleic acid (DNA) to stop it from reproducing and spreading.

Contact Information

Website
www.phicotx.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • Bertarelli Building, Bourn Hall
  • High Street, Cambridgeshire
  • Bourn CB23 2TN
  • England, United Kingdom
+44 01954 000000

Phico Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phico Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
26. Later Stage VC 11-May-2021 $9.7M 000.00 Completed Pre-Clinical Trials
25. Grant 19-Apr-2021 000.00 000.00 Completed Profitable
24. Grant 01-Jun-2020 00000 000.00 Completed Profitable
23. Later Stage VC 14-May-2019 000.00 000.00 000.00 Completed Profitable
22. Grant 01-Aug-2018 00.000 000.00 Completed Profitable
21. Later Stage VC 28-Sep-2017 00.000 000.00 000.00 Completed Profitable
20. Later Stage VC 15-Dec-2016 00.000 000.00 000.00 Completed Profitable
19. Grant 09-Mar-2015 00.000 0000 Completed Profitable
18. Later Stage VC 19-Aug-2014 $2.13M $23M 000.00 Completed Profitable
17. Later Stage VC 17-Dec-2013 $2.62M $20.9M 000.00 Completed Profitable
To view Phico Therapeutics’s complete valuation and funding history, request access »

Phico Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 0,000,000 00.000000 000.0 000.0 00 000.0 0.00
A Ordinary 000,000 00.000000 00.0 00.0 00 00.0 00.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Ordinary 392,156 $0.001300 $3.31 $3.31 1x $3.31 6.67%
Ordinary 714,034 $0.001300 $3.9 $3.9 1x $3.9 12.15%
To view Phico Therapeutics’s complete cap table history, request access »

Phico Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an intravenous-engineered bacteriophage drug designed to treat ventilator-associated pneumonia. The company
Drug Discovery
Bourn, United Kingdom
22 As of 2023
000.00
0000000000 0 000.00

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Barcelona, Spain
00 As of 0000
000.00
00000 00000

000 00

luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Phico Therapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ability Pharma Venture Capital-Backed Barcelona, Spain 00 000.00 00000 00000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
You’re viewing 2 of 2 competitors. Get the full list »

Phico Therapeutics Patents

  • 97

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Phico Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10781441-B2 Modifying bacteriophage Active 08-Apr-2016 000000000
AU-2017245737-A1 Modifying bacteriophage Active 08-Apr-2016 00000000000
CA-3020371-A1 Modifying bacteriophage Pending 08-Apr-2016 00000000000
EP-3440204-A1 Modifying bacteriophage Pending 08-Apr-2016 00000000000
US-20190093100-A1 Modifying bacteriophage Active 08-Apr-2016 C12N15/1037
To view Phico Therapeutics’s complete patent history, request access »

Phico Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Heather Fairhead Ph.D Founder & Chief Executive Officer
Andrew Armour Finance Director
You’re viewing 2 of 5 executive team members. Get the full list »

Phico Therapeutics Board Members (12)

Name Representing Role Since
David Beadle Self Board Member 000 0000
Ian Downing Self Board Member 000 0000
Mark Wilcox Phico Therapeutics Board Member 000 0000
Richard Nagle Self Chairman 000 0000
You’re viewing 4 of 12 board members. Get the full list »

Phico Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Phico Therapeutics Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BGF Growth/Expansion Minority 000 0000 000000 0
CARB-X University Minority 000 0000 000000 0
24Haymarket Venture Capital Minority 000 0000 000000 0
Timothy Rea Angel (individual) Minority 000 0000 000000 0
Winton Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial